These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32221012)

  • 41. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
    Ruemmele P; Dietmaier W; Terracciano L; Tornillo L; Bataille F; Kaiser A; Wuensch PH; Heinmoeller E; Homayounfar K; Luettges J; Kloeppel G; Sessa F; Edmonston TB; Schneider-Stock R; Klinkhammer-Schalke M; Pauer A; Schick S; Hofstaedter F; Baumhoer D; Hartmann A
    Am J Surg Pathol; 2009 May; 33(5):691-704. PubMed ID: 19252434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
    Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
    Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
    Kim J; Kwiatkowski D; McConkey DJ; Meeks JJ; Freeman SS; Bellmunt J; Getz G; Lerner SP
    Eur Urol; 2019 Jun; 75(6):961-964. PubMed ID: 30851984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
    Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
    Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
    Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer?
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Virchows Arch; 2004 Feb; 444(2):135-41. PubMed ID: 14652751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microsatellite instability: an update.
    Yamamoto H; Imai K
    Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.
    Akbari MR; Zhang S; Cragun D; Lee JH; Coppola D; McLaughlin J; Risch HA; Rosen B; Shaw P; Sellers TA; Schildkraut J; Narod SA; Pal T
    Fam Cancer; 2017 Jul; 16(3):351-355. PubMed ID: 28176205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype.
    Pinto M; Wu Y; Mensink RG; Cirnes L; Seruca R; Hofstra RM
    Cancer Genet Cytogenet; 2008 Jan; 180(2):110-4. PubMed ID: 18206535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.
    Poynter JN; Siegmund KD; Weisenberger DJ; Long TI; Thibodeau SN; Lindor N; Young J; Jenkins MA; Hopper JL; Baron JA; Buchanan D; Casey G; Levine AJ; Le Marchand L; Gallinger S; Bapat B; Potter JD; Newcomb PA; Haile RW; Laird PW;
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3208-15. PubMed ID: 18990764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
    Buckley AR; Ideker T; Carter H; Harismendy O; Schork NJ
    Genome Med; 2018 Sep; 10(1):69. PubMed ID: 30217226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Li R; Spiess PE; Gilbert SM; Necchi A
    Eur Urol; 2019 Jul; 76(1):4-6. PubMed ID: 30833139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
    Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
    Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Molecular Pathology of Colorectal Cancer, Microsatellite Instability - the Detection, the Relationship to the Pathophysiology and Prognosis].
    Brychtová V; Šefr R; Hrstka R; Vídeňská P; Bencsiková B; Hanáková B; Zdražilová Dubská L; Nenutil R; Budinská E
    Klin Onkol; 2017; 30(Supplementum1):153-155. PubMed ID: 28471193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The evolving role of microsatellite instability in colorectal cancer: A review.
    Gelsomino F; Barbolini M; Spallanzani A; Pugliese G; Cascinu S
    Cancer Treat Rev; 2016 Dec; 51():19-26. PubMed ID: 27838401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.